Regeneron will acquire 23andMe’s core assets for $256 million, ensuring customer data privacy and continuing the mission of ...

Regeneron acquires 23andMe's genetics services for (Dollar) 256 million * Customer privacy safeguards will remain in place ...

Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, excluding its Lemonaid Health business, as the ...

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.

Regeneron acquires 23andMe for $256 million following its bankruptcy. The deal includes DNA data access, raising privacy ...

Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe ...

Regeneron Pharmaceuticals (NASDAQ: REGN) will acquire bankrupt genetic-testing firm 23andMe in a court-approved auction for ...

Regeneron's win at action means the bankrupt firm's popular DNA-testing service can continue — along with a privacy policy allowing customers to have their data deleted.

Drugmaker acquires DNA testing firm and gains access to massive genetic database ● Consumer genome services to continue; ...

Regeneron acquires bankrupt 23andMe for $256M, taking over its DNA database and services while pledging to uphold privacy ...

Regeneron Pharmaceuticals has said it will preserve the privacy of 23andMe's genetic data after it acquires the DNA testing ...

Regeneron is acquiring “substantially all” of 23andMe’s assets for $256 million following a bankruptcy auction.